Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells

Laura Brunelli, Elisa Caiola, Mirko Marabese, Massimo Broggini, Roberta Pastorelli

Research output: Contribution to journalArticle

Abstract

In non-small-cell lung cancer (NSCLC), one-fifth of patients have KRAS mutations, which are considered a negative predictive factor to first-line therapy. Evidence is emerging that not all KRAS mutations have the same biological activities and possible remodeling of cell metabolism by KRAS activation might complicate the scenario. An open question is whether different KRAS mutations at codon-12 affect cellular metabolism differently with possible implications for different responses to cancer treatments. We applied an explorative mass spectrometry-based untargeted metabolomics strategy to characterize the largest possible number of metabolites that might distinguish isogenic NSCLC cells overexpressing mutated forms of KRAS at codon-12 (G12C, G12D, G12V) and the wild-type. The glutamine deprivation assay and real-time PCR were used to confirm the involvement of some of the metabolic pathways highlighted. Cell clones indicated distinct metabolomic profiles in KRAS wild-type and mutants. Clones harboring different KRAS mutations at codon-12 also had different metabolic remodeling, such as a different redox buffering system and different glutamine-dependency not driven by the transcriptional state of enzymes involved in glutaminolysis. These findings indicate that KRAS mutations at codon-12 are associated with different metabolomic profiles that might affect the responses to cancer treatments.

Original languageEnglish
Pages (from-to)4722-4731
Number of pages10
JournalOncotarget
Volume5
Issue number13
Publication statusPublished - 2014

Fingerprint

Metabolomics
Non-Small Cell Lung Carcinoma
Codon
Mutation
Glutamine
Clone Cells
Metabolic Networks and Pathways
Oxidation-Reduction
Real-Time Polymerase Chain Reaction
Mass Spectrometry
Neoplasms
Therapeutics
Enzymes

Keywords

  • KRAS
  • Mass-spectrometry
  • Metabolomics
  • Mutations
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. / Brunelli, Laura; Caiola, Elisa; Marabese, Mirko; Broggini, Massimo; Pastorelli, Roberta.

In: Oncotarget, Vol. 5, No. 13, 2014, p. 4722-4731.

Research output: Contribution to journalArticle

@article{dfc1f760527f46ab8383fec96536b23b,
title = "Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells",
abstract = "In non-small-cell lung cancer (NSCLC), one-fifth of patients have KRAS mutations, which are considered a negative predictive factor to first-line therapy. Evidence is emerging that not all KRAS mutations have the same biological activities and possible remodeling of cell metabolism by KRAS activation might complicate the scenario. An open question is whether different KRAS mutations at codon-12 affect cellular metabolism differently with possible implications for different responses to cancer treatments. We applied an explorative mass spectrometry-based untargeted metabolomics strategy to characterize the largest possible number of metabolites that might distinguish isogenic NSCLC cells overexpressing mutated forms of KRAS at codon-12 (G12C, G12D, G12V) and the wild-type. The glutamine deprivation assay and real-time PCR were used to confirm the involvement of some of the metabolic pathways highlighted. Cell clones indicated distinct metabolomic profiles in KRAS wild-type and mutants. Clones harboring different KRAS mutations at codon-12 also had different metabolic remodeling, such as a different redox buffering system and different glutamine-dependency not driven by the transcriptional state of enzymes involved in glutaminolysis. These findings indicate that KRAS mutations at codon-12 are associated with different metabolomic profiles that might affect the responses to cancer treatments.",
keywords = "KRAS, Mass-spectrometry, Metabolomics, Mutations, NSCLC",
author = "Laura Brunelli and Elisa Caiola and Mirko Marabese and Massimo Broggini and Roberta Pastorelli",
year = "2014",
language = "English",
volume = "5",
pages = "4722--4731",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "13",

}

TY - JOUR

T1 - Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells

AU - Brunelli, Laura

AU - Caiola, Elisa

AU - Marabese, Mirko

AU - Broggini, Massimo

AU - Pastorelli, Roberta

PY - 2014

Y1 - 2014

N2 - In non-small-cell lung cancer (NSCLC), one-fifth of patients have KRAS mutations, which are considered a negative predictive factor to first-line therapy. Evidence is emerging that not all KRAS mutations have the same biological activities and possible remodeling of cell metabolism by KRAS activation might complicate the scenario. An open question is whether different KRAS mutations at codon-12 affect cellular metabolism differently with possible implications for different responses to cancer treatments. We applied an explorative mass spectrometry-based untargeted metabolomics strategy to characterize the largest possible number of metabolites that might distinguish isogenic NSCLC cells overexpressing mutated forms of KRAS at codon-12 (G12C, G12D, G12V) and the wild-type. The glutamine deprivation assay and real-time PCR were used to confirm the involvement of some of the metabolic pathways highlighted. Cell clones indicated distinct metabolomic profiles in KRAS wild-type and mutants. Clones harboring different KRAS mutations at codon-12 also had different metabolic remodeling, such as a different redox buffering system and different glutamine-dependency not driven by the transcriptional state of enzymes involved in glutaminolysis. These findings indicate that KRAS mutations at codon-12 are associated with different metabolomic profiles that might affect the responses to cancer treatments.

AB - In non-small-cell lung cancer (NSCLC), one-fifth of patients have KRAS mutations, which are considered a negative predictive factor to first-line therapy. Evidence is emerging that not all KRAS mutations have the same biological activities and possible remodeling of cell metabolism by KRAS activation might complicate the scenario. An open question is whether different KRAS mutations at codon-12 affect cellular metabolism differently with possible implications for different responses to cancer treatments. We applied an explorative mass spectrometry-based untargeted metabolomics strategy to characterize the largest possible number of metabolites that might distinguish isogenic NSCLC cells overexpressing mutated forms of KRAS at codon-12 (G12C, G12D, G12V) and the wild-type. The glutamine deprivation assay and real-time PCR were used to confirm the involvement of some of the metabolic pathways highlighted. Cell clones indicated distinct metabolomic profiles in KRAS wild-type and mutants. Clones harboring different KRAS mutations at codon-12 also had different metabolic remodeling, such as a different redox buffering system and different glutamine-dependency not driven by the transcriptional state of enzymes involved in glutaminolysis. These findings indicate that KRAS mutations at codon-12 are associated with different metabolomic profiles that might affect the responses to cancer treatments.

KW - KRAS

KW - Mass-spectrometry

KW - Metabolomics

KW - Mutations

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84905009543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905009543&partnerID=8YFLogxK

M3 - Article

C2 - 24952473

AN - SCOPUS:84905009543

VL - 5

SP - 4722

EP - 4731

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 13

ER -